2-(4-trifluoromethoxyphenyl)oxazole-5-carboxylic acid | 1258269-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-trifluoromethoxyphenyl)oxazole-5-carboxylic acid
• 英文别名: 2-[4-(Trifluoromethoxy)phenyl]-5-oxazolecarboxylic acid；2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole-5-carboxylic acid
• CAS: 1258269-09-8
• 化学式: C₁₁H₆F₃NO₄
• 分子量: 273.168
• InChiKey: KFMOHVOGJCVJSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(4-trifluoromethoxyphenyl)oxazole-5-carboxylic acid 、 1-氨基-3,5-二甲苯 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,5-dimethylphenyl)-2-(4-(trifluoromethoxy)phenyl)oxazole-5-carboxamide
  参考文献：
  名称：

  Subtype-selective Nav1.8 sodium channel blockers: Identification of potent, orally active nicotinamide derivatives

  摘要：

  A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Na(v)1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.121
• 作为产物：
  描述：

  ethyl 2-(4-(trifluoromethoxy)phenyl)oxazole-5-carboxylate 在 水 、 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-(4-trifluoromethoxyphenyl)oxazole-5-carboxylic acid
  参考文献：
  名称：

  Subtype-selective Nav1.8 sodium channel blockers: Identification of potent, orally active nicotinamide derivatives

  摘要：

  A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Na(v)1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.121

文献信息

• ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3896062A1

  公开（公告）日：2021-10-20

  The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.

  本发明涉及一种由通式(I)表示并用作CRBN调节剂的异吲哚啉化合物，以及该异吲哚啉化合物的制备方法、药物组合物和应用。具体而言，本发明提供的一类多取代异吲哚啉化合物，作为一类结构新颖的CRL4CRBN E3泛素连接酶调节剂，具有良好的抗肿瘤活性和免疫调节活性，可用于制备治疗与CRL4CRBN E3泛素连接酶相关疾病的药物。
• [EN] ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND<br/>[FR] COMPOSÉ D'ISOINDOLINE, PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DU COMPOSÉ D'ISOINDOLINE<br/>[ZH] 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2020114482A1

  公开（公告）日：2020-06-11

  本发明涉及一类可用作CRBN调节剂的如通式(I)所示的异吲哚啉类化合物，其制备方法、药物组合物及应用。具体的，本发明提供的一类多取代异吲哚啉类化合物作为一类结构新颖的CRL4CRBNE3泛素连接酶调节剂具有很好的抗肿瘤活性和免疫调节活性，可以用于制备治疗与CRL4CRBNE3泛素连接酶相关的疾病的药物。（I）
• EP3896062
  申请人：——

  公开号：——

  公开（公告）日：——